Business Description
Zelira Therapeutics Ltd
NAICS : 212221
ISIN : AU000000ZLD1
Compare
Compare
Traded in other countries / regions
ZLD.AustraliaZLDAF.USAG1G.Germany IPO Date
2016-12-28Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.33 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.65 | |||||
| Beneish M-Score | -5.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.1 | |||||
| 3-Year EPS without NRI Growth Rate | 27.5 | |||||
| 3-Year FCF Growth Rate | 20.5 | |||||
| 3-Year Book Growth Rate | -23.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.11 | |||||
| 9-Day RSI | 2.79 | |||||
| 14-Day RSI | 10.77 | |||||
| 6-1 Month Momentum % | 25.52 | |||||
| 12-1 Month Momentum % | 7.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | |||||
| Quick Ratio | 0.13 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 1745.68 | |||||
| Days Sales Outstanding | 353.68 | |||||
| Days Payable | 1807.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.1 | |||||
| Shareholder Yield % | 0.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -20.27 | |||||
| Operating Margin % | -2412.96 | |||||
| Net Margin % | -1851.5 | |||||
| ROE % | -16.86 | |||||
| ROA % | -15.68 | |||||
| ROIC % | -22.13 | |||||
| ROC (Joel Greenblatt) % | -599.23 | |||||
| ROCE % | -18.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.48 | |||||
| PB Ratio | 0.36 | |||||
| Price-to-Tangible-Book | 67.41 | |||||
| EV-to-EBIT | -1.86 | |||||
| EV-to-EBITDA | -2.04 | |||||
| EV-to-Revenue | 38.29 | |||||
| EV-to-FCF | -1.59 | |||||
| Earnings Yield (Greenblatt) % | -53.76 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDAF
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zelira Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.202 | ||
| EPS (TTM) ($) | -0.373 | ||
| Beta | 1.98 | ||
| Volatility % | 65.54 | ||
| 14-Day RSI | 10.77 | ||
| 14-Day ATR ($) | 0.021099 | ||
| 20-Day SMA ($) | 0.878253 | ||
| 12-1 Month Momentum % | 7.55 | ||
| 52-Week Range ($) | 0.55 - 1.65 | ||
| Shares Outstanding (Mil) | 11.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zelira Therapeutics Ltd Frequently Asked Questions
What is Zelira Therapeutics Ltd(ZLDAF)'s stock price today?
The current price of ZLDAF is $0.67. The 52 week high of ZLDAF is $1.65 and 52 week low is $0.55.
When is next earnings date of Zelira Therapeutics Ltd(ZLDAF)?
The next earnings date of Zelira Therapeutics Ltd(ZLDAF) is .
Does Zelira Therapeutics Ltd(ZLDAF) pay dividends? If so, how much?
Zelira Therapeutics Ltd(ZLDAF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers